Matthew Baumgardner
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, PI3K/AKT/mTOR signaling in cancer, Biochemical and Molecular Research, Lymphoma Diagnosis and Treatment, Computational Drug Discovery Methods
Most-Cited Works
- → Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity(2013)175 cited
- → Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton’s Tyrosine Kinase Inhibitor(2011)74 cited
- → Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479(2014)38 cited
- → Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.(2013)15 cited
- → Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug(2008)8 cited
- Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor(2011)
- → Preclinical development of the PI3K Alpha selective and PIK3CA Mutant selective inhibitor GDC-0077 and prediction of its human pharmacokinetics(2019)